High levels of S1P are found in endometrial carcinoma, resulting from both the activation of SphK1 and the abundance of its substrate, sphingosine, and there is evidence that SphK1 inhibitors reduce cell proliferation and tumor growth both in vitro and in vivo [79]. This evidence concerns the gene SPHK1 and endometrial carcinoma.